In the context of the COVID-19 pandemic, the Canadian Institutes of Health Research, regrouping 13 institutes, has just selected Oxynov's FreeO2 solution to conduct automated oxygen therapy tests.
Oxygen therapy is the first-line respiratory support for all patients affected by the COVID-19 epidemic and hospitalized. Oxygen therapy is the first-line respiratory support for all hospitalized patients affected by the COVID-19 epidemic and represents a high risk of transmission to caregivers.
FreeO2 allows to automate the ventilation of patients in hospital or at home. In particular, it reduces the burden of monitoring and control for healthcare personnel while ensuring a secure supply of dosages as close as possible to the patient's needs. The coronavirus highlights the value of this solution by optimizing the number of patients under respiratory assistance by considerably limiting physical contact with healthcare personnel.
Oxynov, a French-Quebec company, specializes in the design of innovative medical devices for oxygen therapy. This work is the result of research at Laval University, CHRU Brest and IMT Atlantique.
The company has carried out an incubation phase at the IMT Atlantique Incubator in Brest .
by Mireille Méchineau
